464 related articles for article (PubMed ID: 31431486)
1. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
[TBL] [Abstract][Full Text] [Related]
2. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
[TBL] [Abstract][Full Text] [Related]
3. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
4. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
[TBL] [Abstract][Full Text] [Related]
5. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
6. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
[TBL] [Abstract][Full Text] [Related]
7. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
[TBL] [Abstract][Full Text] [Related]
8. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
9. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
[TBL] [Abstract][Full Text] [Related]
10. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
[TBL] [Abstract][Full Text] [Related]
11. Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study.
Vidal C; Lukas C; Combe B; Berenbaum F; Pers YM; Jorgensen C; Sellam J; Morel J
Joint Bone Spine; 2018 Jul; 85(4):461-468. PubMed ID: 28917996
[TBL] [Abstract][Full Text] [Related]
12. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
[TBL] [Abstract][Full Text] [Related]
13. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
[TBL] [Abstract][Full Text] [Related]
14. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis.
Krabbe S; Glintborg B; Østergaard M; Hetland ML
Scand J Rheumatol; 2019 Mar; 48(2):128-132. PubMed ID: 30102111
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?
Jones GT; Dean LE; Pathan E; Hollick RJ; Macfarlane GJ
Ann Rheum Dis; 2020 Jul; 79(7):914-919. PubMed ID: 32327428
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
17. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
Manica SR; Sepriano A; Pimentel-Santos F; Gouveia N; Barcelos A; Branco JC; Bernardes M; Ferreira RM; Vieira-Sousa E; Barreira S; Vinagre F; Roque R; Santos H; Madeira N; Rovisco J; Daniel A; Ramiro S
Arthritis Res Ther; 2020 Aug; 22(1):195. PubMed ID: 32825839
[TBL] [Abstract][Full Text] [Related]
19. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
